Redbiotec focuses on patients needs only. We therefore actively evaluate partnerning opportunities with the ultimate goal to reinforce our products and/or to add value to therapies of our collaboration partners.
Selected customers and collaboration partners
Further undisclosed big pharma und biotech partners.
Selected technology partners
Redbiotec offers the following partnering opportunities
- Collaborations on projects upon customer’s demand based on Redbiotec’s know-how and technology
- Collaborations in the field of HSV2
- Collaborations in the field of oncolytic viruses and cancer immunotherapies
Please contact us to discuss collaboration opportunities.
With the support from BIA Separations, Redbiotec has been screening different monoliths as newmatrices for its chromatographic steps during the downstream processing of our VLPs.
Redbiotec hold an exclusive license for co-expression technologies of the ETH Zurich.
Redbiotec has a scientific collaboration with GE Healthcare for testing hollow fibers used in the recovery and purification of VLPs.
University of Freiburg
Redbiotec has entered a collaboration with its scientific advisor, Prof. Wilfried Weber, University of Freiburg, to explore further applications of Redbiotec’s rePAX® technology in the field of synthetic biology.
ZHAW (Zurich University of Applied Sciences)
Redbiotec has a longstanding collaboration with the team of Prof. Dr. Ing. Regine Eibl, leader in cell cultivation technique, for the development of state-of-the-art disposable production technology. Developments in this field are continuously integrated into Redbiotec’s rePAX® platform.